Tags : ATR-002

Atriva to Initiate P-II Clinical Study Evaluating ATR-002 for Treatment

Shots: Atriva will commence P-II study assessing ATR-002 vs PBO in hospitalized patients with moderate COVID-19, expected to be initiated in July’2020 ATR-002’s MOA inhibits SARS-CoV-2 viral propagation and prevents the cytokine storm as demonstrated in its preclinical studies. The dual antiviral and immunomodulatory effect allows the therapy to prevent progression to critical-stage COVID-19 in […]Read More